Compare MITT & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MITT | ANIK |
|---|---|---|
| Founded | 2011 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.7M | 191.4M |
| IPO Year | N/A | 1996 |
| Metric | MITT | ANIK |
|---|---|---|
| Price | $7.44 | $14.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 1 |
| Target Price | $9.25 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 325.1K | 110.9K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | ★ 12.60% | N/A |
| EPS Growth | N/A | ★ 80.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $112,819,000.00 |
| Revenue This Year | $4.09 | $5.98 |
| Revenue Next Year | $4.69 | $7.42 |
| P/E Ratio | $9.34 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.63 | $7.90 |
| 52 Week High | $9.27 | $15.45 |
| Indicator | MITT | ANIK |
|---|---|---|
| Relative Strength Index (RSI) | 40.69 | 59.62 |
| Support Level | $7.03 | $13.70 |
| Resistance Level | $7.86 | $15.01 |
| Average True Range (ATR) | 0.25 | 0.46 |
| MACD | -0.00 | -0.15 |
| Stochastic Oscillator | 23.72 | 37.31 |
TPG Mortgage Investment Trust Inc is a real estate investment trust (REIT). It focuses on investing in a diversified risk-adjusted portfolio of residential mortgage-related assets in the U.S. mortgage market. Its objective is to provide attractive risk-adjusted returns to its stockholders over the long term through dividends and capital appreciation. The company focuses on its investment activities on acquiring and securitizing newly-originated residential mortgage loans within the non-agency segment of the housing market.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.